MNKD insider trading
NasdaqGM HealthcareMANNKIND CORP — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About MANNKIND CORP
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Company website: www.mannkindcorp.com
MNKD insider activity at a glance
FilingIQ has scored 491 insider transactions for MNKD since Feb 3, 2015. The most recent filing in our index is dated May 12, 2026.
Across the full history, 77 open-market purchases
and 62 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on MNKD insider trades is 59.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest MNKD Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading MNKD
Frequently asked
- How many insider trades does FilingIQ track for MNKD?
- FilingIQ tracks 491 Form 4 insider transactions for MNKD (MANNKIND CORP), covering filings from Feb 3, 2015 onwards. 33 of those were filed in the last 90 days.
- Are MNKD insiders net buyers or net sellers?
- Across the full Form 4 history for MNKD, 77 transactions (16%) were open-market purchases and 62 (13%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does MNKD insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is MNKD in?
- MANNKIND CORP (MNKD) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.76B.
Methodology & sources
Every MNKD insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.